Amazon, British American Tobacco Fined in Italy Over Smoking Devices Ads
By Mauro Orru
Italy's competition watchdog fined Amazon.com and British American Tobacco, saying the companies had misled consumers when advertising heated-tobacco devices without stressing potential health risks.
The Italian Competition Authority, or AGCM, said Wednesday that the companies advertised BAT's glo hyper X2 and glo hyper air devices by denying, omitting or not highlighting information on nicotine consumption, thus leading consumers to purchase products that carry health risks and are forbidden to minors.
The regulator fined Amazon 1 million euros ($1.1 million) and BAT EUR6 million, calling the companies' conduct "grossly misleading." The decision comes almost a year after AGCM opened a probe into the companies over their advertising practices.
Amazon and BAT didn't respond to requests for comment.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
February 14, 2024 03:45 ET (08:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track